Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease.
about
Interaction between Mesenchymal Stem Cells and B-CellsB cells in chronic graft-versus-host diseaseSustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia.Management of adult immune thrombocytopenia.Monoclonal antibodies in the treatment of autoimmune cytopenias.B cell depletion in autoimmune disease.Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.Chronic graft-versus-host disease: Pathogenesis and clinical management.Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.Clinical utility of rituximab in chronic graft-versus-host disease.Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.Current and future approaches for control of graft-versus-host disease.Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studyChronic graft-versus-host disease: clinical manifestation and therapy.Successful treatment of refractory donor lymphocyte infusion-induced immune-mediated pancytopenia with rituximab.The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigmaEmerging therapies for graft-versus-host disease.Chronic graft versus host disease.Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?Rituximab for steroid-refractory chronic graft-versus-host disease.Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantationTherapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewPrevention of graft-vs.-host diseaseRituximab: applications in dermatology.Oral graft-versus-host disease.Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trialTherapy of chronic graft-versus-host disease.GVHD: a continuing barrier to the safety of allogeneic transplantationTranslational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.Rituximab in hematopoietic cell transplantation.The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.Mechanistic approaches for the prevention and treatment of chronic GVHD.
P2860
Q26750859-04F215F4-CFD1-40D3-B325-57E541562348Q26861706-AF0571CE-4CD6-4D4D-8912-EED38AE9A168Q33338419-5B4BDC56-96CF-4BC7-A2F7-E58EC51FD873Q33339231-6E61A92E-C53F-405A-8412-15A7D103BA3EQ33339746-E8A31EFC-74D4-40F4-BF23-7644B4A88654Q33359539-EDBAEBD6-6161-469E-B617-166D7317D498Q33361142-A1D93E08-B6DD-4B5D-AACB-D6A7D7F83771Q33363326-0D3D53C9-185F-483C-A327-F13EAB1008CCQ33363871-7DD50EFA-74DF-4C31-8DA6-C73BED8C6A1FQ33371639-72C8AD39-8AD4-44BE-9622-87A0644AC2FAQ33375841-FBE05270-0861-448B-90F0-313D4D83B058Q33383124-4B415E5A-078F-41E0-9F35-BB0EDE2337E9Q33385079-7EE2718E-3D58-41EA-97F9-A026B470AD53Q33642625-E4D2BA10-5245-4B3D-810A-61E8CE1D7FD3Q34255166-8EEA03EC-89D3-4BC9-A204-4714D1D84076Q34339695-7024194E-642B-4D24-84D1-89AE2E2819E6Q34613511-8378A2D2-66EC-4E2B-880E-07CD83F8A166Q35084404-519A6F30-A9A7-4CCF-B3B6-CD1184BEC0FDQ35602633-CB786BBC-8A28-45E5-8798-CE86A8B01BE2Q35772587-061055C2-5FC4-4408-BCD4-4A3FE39AB301Q35777619-C1693E40-967A-405B-9281-582A64183E22Q35824478-ED8ED6CB-F489-4AFD-BDFF-BADCF2E58A20Q35848933-86332FEE-3DA4-40EA-A2D8-67355AD815EEQ35970489-C65C3023-4322-4516-BE78-A1490C0F0B8DQ36365485-16C26C49-87EE-45F4-BDBC-A7021A7B4633Q36408216-9FA186AB-63A7-4B1C-B116-63D53A929F6AQ36431047-4ABCE9E5-FDBE-430C-8C4B-879A9715A428Q36623217-BCF49CD1-5EC4-4A52-A433-83D51FBA0B9BQ36932886-CCC41CBA-BFD0-41EA-8D56-B94C44D98DC1Q37144563-91E5B754-DA9B-45D5-95D1-9A904A9AFA0BQ37173479-58486CDE-9C66-41F1-9704-55D8AF35C783Q37369447-5962364B-112E-47F5-AB0A-4EA52ECE71BBQ37552019-A9DD8E29-1D91-4A52-91C5-48F842F24146Q37689179-8B35F562-CE71-4454-AD19-F35D9C1CEAFFQ37702412-C3EBEB9B-3915-4007-90FC-8DBF94B0B8A8Q37737311-757C2227-32CD-4328-B534-67102F07280DQ37738413-6E6CDF0F-6A70-4681-9FA1-810DD2EEE7E6Q37843939-59C66B51-AA52-44A8-A666-E1C13695B6ABQ37899200-9B87A06B-C486-40C4-8BC6-5D9517F86FF3Q39002166-C7CDB6FD-9FFD-4290-995C-65DB3FBC0FCC
P2860
Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@ast
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@en
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@nl
type
label
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@ast
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@en
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@nl
prefLabel
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@ast
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@en
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@nl
P2093
P921
P1476
Anti-CD20 chimeric monoclonal ...... nic graft-versus-host disease.
@en
P2093
Ferrara JL
Ratanatharathorn V
Reynolds C
P304
P356
10.7326/0003-4819-133-4-200008150-00011
P407
P577
2000-08-01T00:00:00Z